Lonza Group AG, the renowned Swiss contract development and manufacturing organization (CDMO), is making significant strides by establishing a global capability centre in Hyderabad, India. This strategic move aligns with the growing trend of multinational pharmaceutical firms creating hubs for digital, scientific, and regulatory support in India.
Strategic Location Choice
The new centre will primarily focus on operational, digital, and scientific functions that support Lonza’s collaborations with pharmaceutical and biotechnology companies. Hyderabad was chosen after a thorough evaluation of multiple locations, thanks to its rich talent pool and robust infrastructure.
Headquartered in Switzerland and founded in 1897, Lonza boasts over 30 development and manufacturing sites across North America, Europe, and Asia, employing close to 20,000 individuals. The company has reported impressive sales figures, with CHF 6.5 billion in revenue and CHF 2.1 billion in core EBITDA as of 2025. Lonza is recognized as a critical partner for pharmaceutical and biotechnology firms that require assistance in developing and producing complex therapies.
Comprehensive Service Offerings
Lonza’s operations cover a broad spectrum of the drug development lifecycle. The company provides extensive services, ranging from early-stage research support to large-scale commercial manufacturing. Their expertise spans various technology platforms, including mammalian biologics, small molecules, bioconjugates, and cell and gene therapies. As the industry continues to evolve, Lonza’s specialized capabilities make it a valuable ally for pharmaceutical companies navigating the complexities of drug development.
The planned capability centre will integrate seamlessly into Lonza’s global framework, enhancing connections between research, development, and manufacturing activities across its various facilities. This initiative comes as Lonza intensifies its focus on its core CDMO business, which plays a pivotal role in the drugmakers’ operational framework.
Growing Market Demand
The pharmaceutical landscape is shifting, with companies increasingly outsourcing drug development and manufacturing to specialized contractors. This trend is driven by the rising complexity and capital intensity of new therapies. Market research indicates that the global CDMO market is poised for significant growth, expected to expand from approximately $258.9 billion in 2025 to around $374.7 billion by 2031.
In India, the contract research, development, and manufacturing (CRDMO) market is also on an upward trajectory. Currently estimated at $12–13 billion, it could potentially grow to $22–25 billion by 2028. This burgeoning sector includes key players like Samsung Biologics, WuXi Biologics, and Catalent, all of which provide outsourced development and manufacturing services to global drugmakers.
Enhancing Manufacturing Capabilities
Lonza has made substantial investments in enhancing its manufacturing capacities and technological capabilities across various global sites. Notable projects include biologics production and bioconjugates manufacturing at its Visp facility in Switzerland, along with cell and gene therapy manufacturing operations in the United States.
As biopharmaceutical manufacturing becomes increasingly complex, companies are turning to specialized teams and digital platforms to coordinate their operations. This includes managing regulatory documentation and supply-chain processes across multiple locations, ensuring streamlined and efficient production.
The Role of Capability Centres
Industry experts recognize that capability centres are essential for modern pharmaceutical operations. These centres support critical functions such as data analytics for drug development, regulatory documentation, and supply-chain management. The growing presence of such centres in India can be attributed to the country’s large pool of skilled professionals in science, engineering, and technology.
Prominent drug manufacturers, including Novartis, Sanofi, and Eli Lilly, have established capability centres in India to bolster their global research and regulatory functions. The country has emerged as a key destination for life sciences capability centres, combining deep scientific talent with advanced digital and analytical capabilities.
Government Support and Future Prospects
Lonza executives recently engaged with key officials from the Government of Telangana to discuss the new centre’s prospects and its potential impact on the local economy. The Telangana government has emphasized the importance of such investments, highlighting Hyderabad’s appeal as a hub for life sciences.
The establishment of this global capability centre is expected to create high-value employment opportunities and further integrate the city into the global biopharmaceutical value chain. For Lonza, the centre promises to generate specialized roles in areas related to pharmaceutical operations, data management, and digital systems.
Conclusion
Lonza’s decision to set up a global capability centre in Hyderabad marks a significant milestone in the company’s journey and highlights India’s growing importance in the global pharmaceutical landscape. As the biopharmaceutical sector continues to evolve, the integration of specialized capabilities and local talent will be pivotal in driving innovation and growth. This initiative not only strengthens Lonza’s operational framework but also solidifies Hyderabad’s position as a vital player in the global biopharmaceutical industry.
- Lonza is establishing a global capability centre in Hyderabad, India.
- The new centre will focus on operational, digital, and scientific functions.
- India’s CRDMO market is projected to grow significantly by 2028.
- Lonza’s investment aims to create high-value jobs and enhance local expertise.
- Capability centres are crucial for modern pharmaceutical operations, supporting data analytics and regulatory functions.
Read more → www.businesstoday.in